Skip to content

Comparison Between Magnetic Field and Laser Therapy in Management of Trigeminal Neuralgia

Magnetic Field and Laser Therapy in Management of Diabetic Trigeminal Neuralgia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05075707
Enrollment
120
Registered
2021-10-13
Start date
2021-10-15
Completion date
2022-02-23
Last updated
2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal Neuralgia

Brief summary

Trigeminal neuralgia (TN) was defined by The International Association for the Study of Pain (IASP) as severe, sudden, usually unilateral, stabbing, brief, recurrent attacks of pain in one or more distributional branches of the trigeminal nerve. The purpose of the current study will to investigate the effect of Low level laser therapy versus electromagnetic therapy on diabetic trigeminal neuralgia pain intensity and amplitude of the compound muscle action potential of the masseter and temporalis muscles in diabetic TN patients.

Interventions

OTHERElectromagnetic therapy.

Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.

Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.

Sponsors

Delta University for Science and Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
25 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* All participants will between the ages of 25 and 45, will of both sexes (male and female), diabetic type two patients with chronic trigeminal neuralgia, (from three to six months). * Patients will awake, cooperative, and free of psychiatric issues (as determined by a psychologist) as well as difficulties resulting from orthopaedic or special sensory deficits.

Exclusion criteria

* Patients will ruled out if they developed TN due to a tumour, herpes zoster, or any other reason other than diabetes, such as significant coagulation dysfunction, cardiopulmonary dysfunction or previous invasive treatment (ethanol, radiofrequency, Gama-knife microvascular decompression, glycerinum injection). * They will not have a previous disability in the face.

Design outcomes

Primary

MeasureTime frameDescription
Studies using electromyography and complex muscle action potentialsat the beginning of the studyAll patients' compound motor action potential amplitudes in the masseter and temporalis muscles will be evaluated before interventions.
Visual analogue scale (VAS)at the beginning of the studyAll the participants were instructed to express their pain by Visual analogue scale (VAS) before the interventions.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026